The company is using technology from Columbia University to develop biologics that can be administered as eye drops, providing a unique and potentially more effective treatment for diabetic retinopathy. Unlike current therapies, which carry risks and require regular injections, Opera Therapeutics' approach aims to prevent damage and cell death associated with diabetic macular edema and retinal vein occlusion. Additionally, the company is exploring the potential of their biologics for treating stroke-induced edema in the brain.